title: The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial.
abstract: A novel rare mutation, homeobox B13 (HOXB13) G84E, was reported to co-segregate with prostate cancer (PCa) in hereditary PCa families and associate with PCa risk in unrelated cases and controls. In this study, we aim to compare the G84E mutation frequency among subjects of different races/ethnicities from various geographic regions in the world and to assess its risk for developing PCa, in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. All the 3508 subjects had initial negative prostate biopsy and were biopsied at Year 2 and 4 for detection of PCa. The G84E mutation was detected only in Caucasians, with the highest carrier frequency in Northern Europe (1.06%), followed by Western Europe (0.60%) and North America (0.31%). No mutation carrier was observed in Southern Europe, Eastern Europe, Latin America, Australia and South Africa. In Caucasians, the G84E mutation frequency was 0.99% and 0.24% in positive and negative biopsy subjects, respectively (P = 0.01). In positive biopsy subjects, the frequency was significantly higher in subjects with a positive family history than those without (4.31% versus 0.34%, P = 0.002). In the 4 year follow-up, the PCa detection rate was 53.8% among the 13 mutation carriers and 22.0% among 3186 non-carriers, relative risk = 2.45 (95% confidence interval: 1.48-4.07). All mutation carriers shared a common haplotype, suggesting a founder effect. In Finland, the G84E mutation was estimated to occur in the year 1792 (95% credible interval: 1735-1831). In conclusion, the G84E mutation of HOXB13, a relatively recent mutation that likely occurred in Northern Europe, significantly increases risk for PCa.
authors: Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
authors: Zhuo
authors: Z
authors: Chen
authors: Celia
authors: C
authors: Greenwood
authors: William B
authors: WB
authors: Isaacs
authors: William D
authors: WD
authors: Foulkes
authors: Jielin
authors: J
authors: Sun
authors: Sigun L
authors: SL
authors: Zheng
authors: Lynn D
authors: LD
authors: Condreay
authors: Jianfeng
authors: J
authors: Xu
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000368:Aged; D001378:Azasteroids / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D000068538:Dutasteride; D018703:Founder Effect; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes / Q000235:genetics; D018398:Homeodomain Proteins / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011471:Prostatic Neoplasms / Q000235:genetics*; D012307:Risk Factors
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D014408:Biomarkers, Tumor; C484414:HOXB13 protein, human; D018398:Homeodomain Proteins; D000068538:Dutasteride
references: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references: 21685461
references: N Engl J Med. 2012 Jan 12;366(2):141-9
references: 22236224
references: Nat Genet. 2009 Oct;41(10):1122-6
references: 19767754
references: Mol Biol Evol. 1993 Sep;10(5):1073-95
references: 8412650
references: Nat Genet. 2007 May;39(5):631-7
references: 17401366
references: Nat Genet. 2008 Mar;40(3):310-5
references: 18264096
references: Nat Genet. 2007 May;39(5):645-9
references: 17401363
references: Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1348-53
references: 22714738
references: Eur Urol. 2014 Jan;65(1):169-76
references: 22841674
references: Bioinformatics. 2002 Jun;18(6):894-5
references: 12075030
references: J Urol. 2004 Oct;172(4 Pt 1):1314-7
references: 15371831
references: Nat Genet. 2009 Oct;41(10):1116-21
references: 19767753
references: Mol Biol Evol. 1987 Jul;4(4):406-25
references: 3447015
references: Nat Genet. 2011 Jul 10;43(8):785-91
references: 21743467
references: Comput Appl Biosci. 1994 Apr;10(2):189-91
references: 8019868
references: N Engl J Med. 2010 Apr 1;362(13):1192-202
references: 20357281
references: J Natl Cancer Inst. 2012 Aug 22;104(16):1260-2
references: 22781434
references: BMC Genet. 2010 May 14;11:39
references: 20470408
references: Nat Genet. 2008 Mar;40(3):316-21
references: 18264097
references: Am J Hum Genet. 2007 Sep;81(3):559-75
references: 17701901
references: Urology. 2003 Dec 22;62(6 Suppl 1):3-12
references: 14706503
references: Cancer Res. 2009 Jan 1;69(1):10-5
references: 19117981